Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia

Cellular and Molecular Neurobiology

Volumn 21, Issue 6, 2001, Pages 799-811

  Avissar, Sofia ^a   Roitman, Gregori ^a   Schreiber, Gabriel ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Clozapine; G proteins; Haloperidol; Parkinsonism; Schizophrenia

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADFX 116; CARBACHOL; CLOZAPINE; DOPAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; ISOPRENALINE; NEUROLEPTIC AGENT; PIRENZEPINE; PROPRANOLOL; PROTEIN SUBUNIT; SULPIRIDE; UNCLASSIFIED DRUG;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINE RELEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LEUKOCYTE; MALE; MONONUCLEAR CELL; NEUROPSYCHIATRY; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SECRETION; PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM;

ADULT; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BRAIN CHEMISTRY; CLOZAPINE; DOPAMINE; DOPAMINE AGONISTS; FEMALE; GTP-BINDING PROTEINS; HALOPERIDOL; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, DOPAMINE; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA; UP-REGULATION;

BACTERIA (MICROORGANISMS); PARKINSONIA;

EID: 0035567928     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015164423918     Document Type: Article

References (52)

1. The role of G proteins in the psychobiology and treatment of affective disorders and their integration with the neurotransmitter hypothesis
2. Reduced Gs protein function and Gas immunoreactive levels in leukocytes of patients with Parkinson's disease
3. Reduced β adrenergic receptor-coupled Gs protein function and Gsa immunoreactivity in mononuclear leukocytes of patients with depression
4. Elevated dopamine receptor-coupled Gs protein measures in mononuclear leukocytes of patients with schizophrenia
5. Magnesium reverses lithium inhibition of beta adrenergic and muscarinic receptor coupling to G proteins
6. Differential G protein measures in mononuclear leukocytes of patients with bipolar mood disorder are state dependent
7. Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression
8. Normalization dynamics by electroconvulsive treatment of reduced G protein levels and functions in mononuclear leukocytes of patients with major depression
9. Muscarinic receptor subclassification and G proteins: Significance for lithium action in affective disorders and for the treatment of the extrapyramidal side effects of neuroleptics (Bennett Award Paper)
10. The involvement of G proteins in the pathogenesis and treatment of affective disorders
11. Interaction of antibipolar and antidepressant treatments with receptor-coupled G proteins
12. Measurement of early events in signal transduction beyond receptors involving G proteins function in mononuclear leukocytes
13. G protein measurements: An empirical tool for the diagnosis of affective disorders
14. Carbamazepine and electroconvulsive shock attenuate beta-adrenoceptor and muscarinic cholinoceptor coupling to G proteins in rat cortex
15. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex
16. The effects of seasons and light therapy on G proteins levels in mononuclear leukocytes of patients with seasonal affective disorder
17. Functional and quantitative measures of receptor coupled G proteins in human mononuclear leukocytes: No change with age
18. 1A dopamine receptor from Gs protein
19. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
20. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects
21. Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes
22. G proteins: Transducers of receptor-generated signals
23. Effects of chronic treatment of haloperidol and clozapine on levels of G proten subunits in rat striatum
24. G proteins
25. Mechanisms of lithium action
26. Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence
27. Affinity of neuroleptics for D1 receptor of human brain striatum
28. Change in platelet GTP-binding protein in drug-free depressed patients
29. Lithium and haloperidol treatments differently affect the mononuclear leukocyte Gs alpha protein levels in bipolar affective disorder
30. Chronic treatment with antipsychotic drugs does not alter G protein alpha or beta subunits levels in rat brain
31. Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics
32. 3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes
33. 3H]cAMP binding sites and decrease in Gi alpha and Go alpha immunoreactivities in left temporal cortices from patients with schizophrenia
34. G-proteins (Gi, Go) in the basal ganglia of control and schizophrenic brain
35. Reduced concentrations of the alpha-subunit of GTP-binding protein Go in schizophrenic brain
36. Dopamine D5 receptors in human peripheral blood lymphocytes: A radioligand binding study
37. G proteins as a biochemical tool for diagnosis and monitoring treatments ofmental disorders
38. Lithium-selective alteration of brain vs. cardiac Gs protein function
39. Hyperfunctional G proteins in mononuclear leukocytes of patients with mania
40. Chronic haloperidol does not alter G protein alpha subunit levels in rats
41. Dopamine receptors-clinical correlates
42. Antipsychotic drug dose and neuroleptic/dopamine receptors
43. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain
44. Changes in G protein levels in the hippocampus and the striatum of rat brain after chronic treatment with haloperidol and sulpiride
45. G protein levels and function as an objective measure of depression in patients with functional bowel disorders
46. 5 dopamine receptor gene and transcribe the two pseudogenes
47. Dopamine receptor antagonists
48. Clozapine
49. Isotype-specific G protein abnormalities in the left superior temporal cortex and limbic structures of patients with chronic schizophrenia
50. Mononuclear leukocyte levels of G proteins in depressed patients with bipolar disorder or major depressive disorder
51. Cerebral cortex Gs protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder
52. sa subunit levels are elevated in bipolar affective disorder